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We investigated the readiness to quit and the smoking cessation rates of smokers requring
bronchoscopy and receiving advice quitting. This randomized controlled trial evaluated the
effectiveness of two smoking cessation interventions, either a brief advice (control group),
or a longer support, delivered at the time of bronchoscopy.
Weconsecutively enrolled233adult smokers, regardless of the initial level ofmotivation toquit.
Their mean (SD) age was 57 (12) years; males were 192. They had smoked a median of 44.5 pack-
years. Their mean (SD) Fagerstrom score was 8 (2). There was no difference between groups.to reach smokers at a time when they may be more receptive to advice quitting due to the perceived
oking related disease.
7 586760; fax: þ39 577 586196.
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62 P. Martucci et al.Surprisingly, 45% of participantswere in the action stage at baseline; these 105 subjects had quit in
theweek immediatelyprior to thebronchoscopy.At6-and12-months follow-upvisits, respectively
41% and 29% of participants in the intervention group and 27% and 13% in the control group objec-
tively showed a 1-week point prevalence abstinence. The difference was significant at 6 months
(p< 0.05) but not at 1-year visit (pZ 0.052), even if there was a trend towards greater cessation
rate in the intervention group. Inmultivariable logisticmodels, at the final visit being a quitterwas
positively associated with having been in the action stage at baseline and negatively with the
Fagerstrom score and the presence of smokers in household.
We conclude that the time of bronchoscopy may possibly predispose smokers to quit. Further
efforts are needed to clear whether more protracted support might achieve higher long-term
smoking cessation rates.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Tobacco smoking is a major preventable cause of increased
morbidity and mortality; quitting always leads to a significant
gainof lifeexpectancy.Unfortunately, smoking iswidespread:
a quarter of adults are continuing to smoke in developed
countries. Most smokers wish to quit and have tried at least
once, but only 2e4% yearly succeed in stopping. Nicotine
addiction is a primary cause of failure formost unassisted quit
attempts.1 Health care givers have a key-role to increase
smoking cessation rates. Physician advice for smoking cessa-
tion approximately doubles the rate of long-term quitting.2
Guidelines recommend that smokers who were attending
hospital for an examination should regularly receive oppor-
tunistic advice to quit.3
Bronchoscopy is usually conducted on ambulatory basis
in hospital or during hospitalization. Although it is a rela-
tively common examination, to our knowledge, no previous
study did evaluate whether it may trigger smoking cessa-
tion. We postulated that, at the time of bronchoscopy,
smokers may be susceptible to change their smoking status
and receptive to smoking cessation interventions. We have
evaluated the effectiveness of two interventions delivered
at the time of bronchoscopy, either a brief notification, or
a longer support against smoking. Because of ethical
concerns of not addressing smoking cessation programmes
with this high-risk population, we have applied brief advice
to quit as control condition rather than no intervention.
Likewise, short length support, defined as brief advice
occurring as part of routine care, is known to produce lower
cessation rates compared with more intensive interven-
tions.2 The primary outcome was the objective assessment
of point prevalence abstinence at 1-year of study entry.4
Secondary outcomes are self-reported abstinence and
changes in daily consumption of cigarettes from quit date
to the final visit. The impact of bronchoscopy on smoking
status and the identification of demographic and behavioral
correlates of motivation to quit have been analyzed.Material and methods
Recruitment
From January 2006 to June 2006, we consecutively enrolled
adult eligible patients attending for a bronchoscopy ateight Italian Hospitals. We have included all subjects who
declared having smoked at least 1 cigarette within
a 1-month period before bronchoscopy, regardless of their
level of motivation to quit. Because patients who were
recent ex-smokers remain at high risk for relapse, they
were also enrolled. We excluded smokers with a medical
history reporting alcohol or drug abuse. Informed consent
was obtained from all eligible patients at the time of initial
interview. The study was approved by Ethics Committee of
the participant Centers. The initiative was endorsed by the
Italian Association of Hospital Pulmonologists.
Assessment interview and tests
Immediately before the bronchoscopy using a standard-
ized questionnaire we collected some demographic vari-
ables (i.e. age, sex, educational level) and health data
(i.e. co-morbidities and reasons of admission to bron-
choscopy); smoking history, nicotine addiction level
measured by the Fagerstrom Test for Nicotine Depen-
dence (FTND,5), the reasons to smoke evaluated by the
Horn test6; the readiness to stop smoking using the stage
of change algorithm by DiClemente,7 some other reasons
known to influence eventual relapse with particular
reference to social and family environment. Exhaled CO
measurements were performed using the EC50 Smoker-
lyser (Bedfont Technical Instruments Ltd., Sittingbourne,
Kent, UK) in parts per million (ppm) in accordance to
standardized method.8
Support given to participants
Then investigators randomly allocated eligible patients to
either the intervention group or the usual care (control)
group. In order to standardise the intervention, all inves-
tigators participated in a preliminary meeting held imme-
diately before the study starting. In two participating
centers the interventions were conducted by the physicians
of the anti-smoking clinics. For each center the smoking
cessation intervention was always provided by the same
physician and administered immediately before the bron-
choscopy. Subjects in the control group received verbal
advice to stop smoking with added generic information
about the harmful effects of smoking lasting less than
5 min. Subjects in the intervention group received a more
intensive support, consisting of a 15-min individually
Table 1 Some baseline characteristics of the study
participants.
Characteristics Percentage of total (%)
Educational attainment
Less than primary school 38
Primary school diploma 39
High school diploma or higher 23
Marital status
Married 84
Divorced/widowed/
separated/single
16
Social class
Employees 46
Retired 40
Unemployed 14
Co-morbidities
Coronary artery disease 6
Chronic obstructive
pulmonary disease
36
Asthma 3
Diabetes mellitus 6
Hypertension 26
Cancer 3
History of peptic ulcer 25
Interstitial lung diseases 2
Obstructive sleep
apnea syndrome
1
Bronchiectasis 2
Main cause requiring bronchoscopy
Suspected cancer 65
Pneumonia 16
Suspected tuberculosis 3
Interstitial lung diseases 2
Pleural effusion 3
Lymphoadenopathy 3
Coin lesions 3
Other reasons 5
Smoking cessation in patients requiring bronchoscopy 63tailored counseling and a further 15-min advice within
24e72 h after bronchoscopy; in the first part of the inter-
vention enrolled subjects were counseled about the risk of
smoking for their health, reviewing the benefits of quitting
and giving motivation to quit; after bronchoscopy, the same
message was reinforced with the emerging data from
bronchoscopy as well as tailored cognitive-behavioral
support (i.e., some strategies to disrupt cues to smoke, how
to cope with negative mood or urge to smoke associated
with the withdrawal syndrome and to prevent relapse).
Only patients in the intervention group received both
written information by a booklet ‘‘Stop Smoking. A Help to
be successful’’ designed to give information about smoking
addiction, abstinence symptoms and how to cope with
them without intensive contact with a therapist, and
contact details of the local smoking cessation service for
further eventual help. A pharmacological therapy was
suggested, but prescribed only on demand.
Outcomes
All enrolled patients were called by phone, even several
times if necessary, for a monitoring interview at 6 and 12
months after the trial entry to assess changes in smoking
status, medical problems and health status. If subjects
quit congratulations were given; if the subjects were still
smoking, the best strategy to quit was briefly discussed. If
a patient reported not smoking even a puff for at least 1
week before 6 or 12-month contact, he or she was clas-
sified as non-smoker by self-report. Subjects were invited
to the center for measuring the expired CO. Abstinence
was defined by exhaled carbon levels of monoxide con-
centration 10 ppm. We analyzed data on an intention-
to-treat basis, in which all participants, unless they have
died, were evaluated. Participants who were lost during
follow-up were considered as persistent smokers, as our
goal will be to obtain full follow-up data on all partici-
pants.4 At 1-year follow-up, patients in the intervention
group were asked to express their adherence to the advice
and their satisfaction about this smoking cessation
intervention.
Statistical analysis
To analyze smoking cessation outcomes of this trial, for
each result a chi-square test was carried out to compare
the two groups. Multivariate regression analysis was used to
examine the association between cessation outcomes and
predictor variables. Forward stepwise selection was used to
choose significant interaction terms at the 5% level after
entering all the main effects in the model. Unless stated
otherwise, data is presented as the mean SD. A p-value of
<0.05 was considered as significant. All the analyses were
performed using the statistical package Stata 8 on a PC-
compatible personal computer (Stata corporation, College
Station, TX, USA).
Results
We have enrolled 233 subjects. Their mean (SD) age was 57
(12) years; males were 192, females were 41. Somedemographic and clinical baseline characteristics of
enrolled subjects are reported in Table 1. Overall, the
presence of co-morbidities was high (73% of participants).
The flow chart of the trial is reported in Fig. 1. Some
baseline smoking characteristics are displayed in Table 2.
Subjects had smoked a median of 44.5 pack-years (25% and
75% centiles: 27 and 60). All 105 subjects in the action stage
had quit in the week immediately prior to the bronchos-
copy; their mean (SD) levels of exhaled carbon monoxide
was 4.8 1.8 ppm (vs. 9.9  5.6 ppm for the remainings,
p< 0.0001). The Fagerstrom score was strongly correlated
with the domains of dependence (pZ 0.0002) and habits
(pZ 0.0008), but not with those of handling, stimulation,
tension reduction or pleasure-relaxation of the Horn test.
At the time of bronchoscopy there was any difference in
age, gender, educational attainment, concomitant
co-morbidities, cause requiring bronchoscopy (including
suspected cancer, or the presence of haemoptysis), smoked
233 Patient randomized
117 control group 116 intervention group
9 Died
22 Lost to follow-up 8 Died
20 Lost to follow up
86 Assessed at 6 months
79 Objective confirmation 88 Assessed at 6 months78 Objective confirmation
66 Assessed at 12 months
56 Objective confirmation
9 Died
13 Lost to 
follow-up  
10 Died
10 Lost to 
follow-up  
68 Assessed at 12 months
60 Objective confirmation
Figure 1 Flow chart of trial.
64 P. Martucci et al.pack-years, Fagerstrom score, presence of smokers in
household neither between treatment groups, nor between
quitters and smokers.
The main results between treatment groups are reported
in Table 3. The difference was significant at 6 months, but
not at 1-year follow-up visit. At the final visit smokers
smoked a mean (SD) number of cigarettes per day
(15 10) lower than at baseline (p< 0.0001). According to
the smoking stage of change at baseline, the percentage of
quitters at 1-year follow-up was, respectively, 58% for
subjects in the action stage, 26% for those in the preparation
stage, 14% for contemplators and 18% for pre-contempla-
tors. In multivariable logistic models, being a nonsmoker at
both 6 and 12 months was associated with having been in the
action stage at baseline (respectively OR 3.50 1.15 and
6.94 2.99, p< 0.001) and negatively with the presence of
smokers in household (respectively OR 0.64 0.12 and
0.43 0.13, p< 0.05). Interestingly, only having recently
quit at baseline was significantly associated to 1-year
smoking cessation, but not having attempted to quit in the
previous year or willingness to quit in the future. At 1-year
follow-up being a drop-out was significantly associated with
having cancer (OR 3.15 1.43, pZ 0.012) and negatively
associated with having been in the active stage at baseline
(0.54 0.17, pZ 0.05). Being a smoker was slightly associ-
ated with the Fagerstrom score at baseline (1.19 0.10,
p< 0.05). These associations remained significant after
adjustment for center of recruitment. No association was
found with age, gender, schooling, any of the domains of the
Horn test, presence of haemoptysis at baseline, or group of
randomization. We did not observe any difference of quit
rates among different respiratory disease diagnosis or
symptoms. At 1-year follow-up quitters reported higher
rates of health recovery or better health status than
persistent smokers (80 vs. 30%, p< 0.001). Respectively,
58% and 10% of subjects in the intervention group reportedthat they had fully or partially followed the recommenda-
tions for quitting received at baseline; only two subjects
have used pharmacological help (nicotine gum and bupro-
pion). Nevertheless, 97% of quitters rated the intervention
as somewhat or very useful vs. 71% of smokers (p< 0.001).Discussion
The main result of the present survey is that smokers who
underwent bronchoscopy and received physician advice
quitting showed high motivation to quit and high rates of
smoking cessation. These subjects, not necessary ready to
quit or even thinking of it previously, have had a recent
change in their health requiring the need for bronchoscopy.
This event seems to predispose smokers to quit. Although
health is a commonly cited reason for quitting, the result
was not obvious: the suspicion of a smoking related-disease
and the same invasive procedure of bronchoscopy certainly
increased the level of anxiety to which our subjects could
react increasing smoking. Smoking is a coping strategy to
deal with stress and smokers addicted to nicotine might
also increase smoking at the time of an acute health crisis.
For instance, a previous survey did not find any effect of
physician advice given to patients attending emergency
department.9 Likewise, smokers are known to underesti-
mate their personal risks of smoking related diseases. The
high rate of co-morbidity affecting our subjects also
confirms that many participants of our sample who, by
smoking, were likely to exacerbate their chronic health
problem were continuing to smoke before requiring bron-
choscopy. Our survey has shown that nicotine dependence
was related to the smoking cessation rate only at 1-year
follow-up. This finding is not new; measures of nicotine
dependence are more strongly associated with smoking
cessation only in the long-term period.10 Likewise, nicotine
Table 2 Some baseline smoking characteristics of the
study participants.
Stage of readiness to change
smoking status
Percentage
of total
Pre-contemplation 14
Contemplation 13
Preparation 28
Action 45
At least one previous attempt to quit 21
Previous enquiry about smoking status
from health caregivers
93
Receivers of previous advice quitting
from health caregivers
91
Receivers of previous booklets
with information to promote
smoking cessation
6
Previous participation in a smoking
cessation program with a quitting plan
0
Other smokers
in household
67
Mean (SD)
Cigarettes smoked per day
during the previous year
26 (1)
Numbers of pack-years 39 (14)
Age of initial smoking 17 (0.7)
Fagerstrom score 8 (2)
Horn test score
Stimulation 5.1 (0.3)
Pleasure/Relaxation 5.5 (0.2)
Tension reduction 6.6 (0.2)
Dependence 7.3 (0.3)
Habits 3.5 (0.2)
Handling 4.3 (0.2)
Table 3 Main results between groups at 6- and 12-months
follow-up visits.
Variable Numbers (% of total)
Intervention Control
Baseline visit
Self-reported point
prevalence cessation
52 (45) 53 (45)
6-months control
Self-report cessation
point prevalence
51 (47) 39 (36)
Objective confirmation
by exhaled CO*
44 (41) 29 (27)
12-months control
Self-report cessation
point prevalence
32 (33) 21 (21)
Objective confirmation
by exhaled CO**
28 (29) 13 (13)
*pZ 0.012; **pZ 0.052.
Smoking cessation in patients requiring bronchoscopy 65dependence is only a factor for a successful quit attempt.
Other influences, such as cognitive, affective and environ-
mental factors, are important.11 In our survey the risk of
relapse was strongly associated to the presence of smokers
in household.
It is generally recognized that the more time is spent with
smokers the greater the effect in aiding cessation rates.12
Brief advice usually has its great value to increasemotivation
quitting; tailored, more intensive support should help to
cope with withdrawal symptoms and prevent relapse. As
most of our patients have tried quitting at the time of
intervention, we thought that more intensive support could
assure a greater rate of abstinence. Effectively, at 6-months
follow-up the rate of smoking cessation in the intervention
group was higher than that of the controls. At the final visit
we did not find differences in smoking cessation rates
between groups, although a trend toward a greater absti-
nence rate remained in the intervention group. We must
highlight that the failure to show a significant difference
between treatment groups was likely associated with an
insufficient statistical power in the study. We believe that
there was a possibility of a type II error, but, as no previous
study did analyze the value of smoking cessation interven-
tions for smokers requiring bronchoscopy, we did notestablish a power analysis and our sample sizewas based only
on a convenience basis, such as the 6-months duration of
study entry. However, our results are consistent with ameta-
analysis of results from 21 trials that included >7000
participants where there was no significant benefit gained
with intensive counseling compared to brief advice.13 Simi-
larly, our intensive, but transient, support did not succeed in
offering more additional help than brief advice. Further
efforts are needed to focuswhethermoreprotracted support
together with pharmacological treatment and scheduled
follow-up contacts may possibly achieve higher long-term
smoking cessation rates.
As expected, smoking cessation was associated to better
overall health status, fewer clinic visits, and fewer
smoking-related hospital admission. Likewise, it is known
that smoking cessation or reduced cigarette consumption
have a beneficial effect on the remission of respiratory
symptoms even in lung cancer patients.14,15
We conclude that physician advice at the time of bron-
choscopy is a good time for promoting smoking cessation
when subject health is perceived as salient. Further efforts
are needed to convert temporary cessation into longer
abstinence rates and to emphasize the factors useful to
maintain successful quitting.Conflict of interest
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